THE EARLY DETECTION RESEARCH NETWORK: BIOMARKER DEVELOPMENTAL LABORATORIES RELEASE DATE: August 27, 2004 RFA Number: RFA-CA-05-023 Update: The following update relating to this announcement has been issued: June 26, 2009 - This RFA has been reissued as (RFA-CA-09-017). EXPIRATION DATE: December 21, 2004 Department of Health and Human Services (DHHS) PARTICIPATING ORGANIZATION: National Institutes of Health (NIH) (http://www.nih.gov) COMPONENT OF PARTICIPATING ORGANIZATION: National Cancer Institute (NCI) (http://www.nci.nih.gov/) CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.394 LETTER OF INTENT RECEIPT DATE: November 22, 2004 APPLICATION RECEIPT DATE: December 20, 2004 This RFA is a reissue of RFA CA-04-006, which was published in the NIH Guide on September 22, 2003. THIS RFA CONTAINS THE FOLLOWING INFORMATION o Purpose of this RFA o Research Objectives o Mechanism of Support o Funds Available o Eligible Institutions o Individuals Eligible to Become Principal Investigators o Special Requirements o Where to Send Inquiries o Letter of Intent o Submitting an Application o Supplementary Instructions o Peer Review Process o Review Criteria o Receipt and Review Schedule o Award Criteria o Required Federal Citations PURPOSE OF THIS RFA The Division of Cancer Prevention (DCP), National Cancer Institute (NCI), invites new and competing renewal cooperative agreement and NIH intramural applications to continue the national Network that has the responsibility for the development, evaluation, and validation of biomarkers for earlier cancer detection and risk assessment. Biomarkers are defined as cellular, biochemical, and molecular (including genetic and epigenetic) alterations by which a normal, abnormal, or simply biologic process can be recognized or monitored. Biomarkers are measurable in biological media, such as in tissues, cells, or fluids. The Network has four main components – Biomarker Developmental Laboratories (BDL), Biomarker Reference Laboratories (formerly known as Biomarker Validation Laboratories), Clinical Epidemiology and Validation Centers (formerly known as Clinical and Epidemiologic Centers), and a Data Management and Coordinating Center (DMCC). The Biomarker Developmental Laboratories have responsibility for the development and characterization of new, or the refinement of existing, biomarkers and assays. The Biomarker Reference Laboratories serve as a Network resource for clinical and laboratory validation of biomarkers, including technological development and refinement. The Clinical Epidemiology and Validation Centers collaboratively conduct clinical and epidemiological research on the Network-wide clinical validation of biomarkers. The Data Management and Coordinating Center supports statistical and computational analysis, informatics infrastructure, and coordinates network-wide meetings and conferences. For further details, see http://www.cancer.gov/edrn. The EDRN Steering Committee (SC) is composed of the Principal Investigators (PIs) in the Network and appropriate NCI staff to coordinate the work of the Network. The purpose of this reissuance is to invite new and competing renewal applications to add additional Biomarker Development Laboratories and to ensure biomarker studies on all cancers of common occurrence are supported. Special emphasis should be placed on cancers of common occurrence, with high priority given to studies of breast, lung, ovarian, colon, pancreatic, and prostate and other less prevalent epithelial cancers, which are the major causes of cancer- related mortality and have yet to be controlled with screening and prevention. Separate RFAs had already been issued to establish the Biomarker Reference Laboratories, Clinical Epidemiology and Validation Centers, and the Data Management and Coordinating Center. Applicants are encouraged to participate in more than one component, because it is recognized that collaboration already exists in individual institutions for clinical testing and validation of biomarkers/reagents. RESEARCH OBJECTIVES A. Background The Network has a straightforward mission: to translate newly emerging molecular knowledge into practical clinical tests to detect cancer and cancer risk. For most cancers, successful treatment depends on early detection and successful prevention depends on the accurate evaluation of risk. The Early Detection Research Network (EDRN) seeks to give treatments the opportunity to work and to make prevention possible. The Network is using cutting-edge technologies to identify the changes that occur in the earliest stages of transformation of a normal cell into a cancerous cell. Scientific expertise from leading national and international institutions has been harnessed to first identify, and then validate, crucial molecular markers to detect cancer and to assess cancer risk. The Network is an investigator-initiated Network for collaborative research created to link the discovery of biologic markers directly to the next steps in the process of developing early detection tests. The power of bioinformatics and computer- assisted programs is being put to full use to analyze Network data and to produce answers to key questions more quickly. The use of new technologies, such as genomics, epigenomics, and proteomics allows the identification of genetic as well as antigenic changes during the early stages of malignant progression. Some of these changes show promise as biomarkers of preneoplastic development or of early malignant transformation. The application of these emerging technologies in the field of early detection and risk assessment is a high priority in the NCI’s strategy for reducing mortality from cancer. Early detection of cancer has been identified as an area of extraordinary opportunity for research investment in the NCI 2004 Bypass Budget (http://plan.cancer.gov/). The Network is an opportunity and a challenge for the scientific community – an opportunity to make science work for people and a challenge to make this new model of collaboration a productive scientific construct. Collaborations and partnerships that are necessary for our ultimate success of this project have been put into place. The acceleration of scientific progress through the Network is faster than it has ever been; consequently, the need for clinical application is now greater than ever. Early detection technologies are also rapidly evolving while existing technologies are undergoing progressive refinement in their sensitivity, specificity, and high-throughput. Improved analytic tools have allowed a more detailed examination of the molecular basis of carcinogenesis and have provided the ability to identify the molecular and cellular signatures of cancer and to explore the gene-environment interactions relevant to early detection. To explore fully the application of molecular profiles for earlier detection and risk assessment, it is essential to understand the molecular pathogenesis of cancer, that is, the natural history of tumor progression at the molecular level, so that the biological behavior of an evolving lesion (i.e., dysplasia or field change) can be predicted with greater accuracy. Current observations indicate that cancers usually evolve through many complex cellular processes, pathways, and networks. A better understanding of the circuits in these pathways is critical if we are to successfully apply these molecular-based technologies to earlier detection. Since its inception in 1999, the EDRN has followed a “vertical” approach to biomarker research — that is, an established, integrated, multidisciplinary environment that would facilitate collaboration among technology developers, basic scientists, clinicians, epidemiologists, biostatisticians, and other health professionals, and therefore would expedite efficacious clinical applications of the molecular knowledge that has burgeoned in recent years (Srivastava, 1999). The Network has produced a system for evaluating biomarkers as tools to clinically detect cancer before symptoms appear, and to identify people at risk (http://www.cancer.gov/edrn). A five-phase approach has been established as a standard and a road map for successfully translating research on biomarker applications from the laboratory to the bedside (Pepe, M.S., Etzioni, R., Feng, Z., Potter, J., et. al.,. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 93, 1054-1061). These phases are: Phase I: exploratory studies to identify potentially useful biomarkers – (i.e., the “discovery” phase); Phase II: biomarkers are studied to determine their capacity for distinguishing between people with cancer and those without – (i.e., the “validation” phase); Phase III: studies to assess the capacity of a biomarker to detect preclinical disease by testing the marker against tissues collected longitudinally from research cohorts; Phase IV: prospective screening studies; and Phase V: definitive large-scale population studies to determine the overall impact of screening on health outcomes in the target population. Significant progress has been made by the EDRN investigators from discovery to development, to validation, and to application. The pace at which molecular signatures, (e.g., proteomics, genomics) associated with causal pathways and processes are identified is accelerating. However, major challenges remain in integrating these discoveries and developments into clinical practice. The Network stimulates collaborative research to meet this challenge by supporting translational research. For further research activities across the Network, see http://www.cancer.gov/edrn. Applicants are encouraged to see the EDRN second progress report at http://www3.cancer.gov/prevention/cbrg/edrn/edrn_report2002.pdf. Applicants are strongly encouraged to forge partnerships with industry, including biotechnology firms, to develop biomarkers, reagents, technologies, and assays. The Network continues to serve as an attractive source of collaborations for industry, since it will provide clinical opportunities for the evaluation of new technologies. The Network will encourage collaborations with industry in order to leverage funds awarded under this RFA. NCI funds will be used to support the underlying infrastructure and the cost of studies not having direct implications for a company’s product development or marketing strategy. NCI views partnerships with industry as an important component of the EDRN mission. However, with respect to new technologies and/or reagents provided by such participants that are part of development or product plans, the individual companies will be responsible for costs in such areas as technology standardization and quality assurance as well as scale-up of laboratory techniques, collection and formatting of specialized data required by regulatory agencies for device approvals, preparation of registration documents, and supporting a portion of the accrual to studies pivotal for registration. B. Network Administrative Structures Network Organization: Structured around four main components, the Network currently includes 18 Biomarker Developmental Laboratories (BDLs), three Biomarker Reference Laboratories (BRLs), nine Clinical and Epidemiologic Validation Centers (CEVCs), and a Data Management and Coordinating Center (DMCC)(The Early Detection Research Network: Translational Research to Identify Early Cancer Risk; NCI Publication No. 01-4852, August 2001). o The Biomarker Developmental Laboratories develop and characterize new biomarkers, or refine existing biomarkers (Phase I and Phase II). (See previous BDL RFA at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-04-006.html.) o The Biomarker Reference Laboratories serve as a resource for the clinical and analytical validation of biomarkers, including development of technology, standardization of assay methods, and refinement of existing methods. (See previous BRL RFA at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-009.html.) o The Clinical Epidemiology and Validation Centers conduct early phases (Phase II and Phase III) of clinical validation and epidemiological research into the application of biomarkers. (See previous CECV RFA at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-005.html.) The Data Management and Coordinating Center provides statistical, logistics, and informatics support and develops the theoretical and statistical approaches to the simultaneous pattern analysis of multiple markers. (See previous RFA DMCC at http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-99-011.html.) Four federal agencies participate in the EDRN through interagency agreements: the National Institute of Standards and Technology (NIST), which serves as a validation laboratory; the Centers for Disease Control and Prevention (CDC) which serves as a Clinical and Epidemiologic Center; the Food and Drug Administration (FDA); and the Jet Propulsion Laboratory (JPL), National Aeronautics and Space Administration (NASA), which provides informatics support. Each component is funded through a separate RFA. An applicant, however, may seek funding to participate in more than one component. Each awardee will conduct independent research using their U01 funds and collaborative research using the Core Funds from the Headquarters (see definition of a Headquarters below) and from the set-aside funds in their U01 pending approval by the Steering Committee and release by the NCI, respectively. Each laboratory/center will be managed by a PI and may include academic and industrial biotechnology investigators who are involved in cancer detection and diagnostic research. In order to expedite the translational research, the Network will be supplemented by the ad hoc participation of additional investigators (academic or community-based) who are able to validate the results of laboratory studies through patient accrual. Currently, the Network consists of experts in basic molecular science, laboratory technology, clinical studies, biometry, and epidemiology. The expertise in laboratory science includes conducting research on the biology of incipient neoplasia encompassing the development, characterization, and testing of biomarkers of early cancer and risk and developing of relevant technologies for biomarker detection, and analytical tools for the evaluation of biomarkers for detection, and risk assessment. The expertise in laboratory validation includes knowledge and practice of Standard Operating Procedures (SOPs), and experience in the statistical evaluation of accuracy, precision, reproducibility, and performance characteristics of tests in multi-center settings. Expertise in patient accrual and associated clinical issues for studies will be needed to apply basic science discoveries to clinical settings. Computational and informatic needs of the Network are provided by a Data Management and Coordinating Center and the JPL. Steering Committee: The Steering Committee (SC) has responsibility for scientific management and oversight, including monitoring the activities of the DMCC. For administrative structure, and responsibilities of the Steering Committee, see “Collaborative Responsibilities.” Network Consulting Committee (NCC): A separate advisory committee has been established by the NCI to ensure that the overall Network is adequately responsive to promising opportunities, exhibits the desired degree of flexibility in composition and decision-making, and makes prioritization decisions free from conflicts of interest. For further details, see “Collaborative Responsibilities.” Data Management and Coordinating Center (DMCC): The Data Management and Coordinating Center provides logistic support for the conduct of the SC and NCC meetings, provides statistical and data management support for protocol development, conducts analyses of clinical data, and develops informatics (i.e., information technologies). It studies applied and theoretical approaches to the simultaneous analysis of multiple markers. In addition, the DMCC, in collaboration with JPL and EDRN investigators, has developed common informatics, Common Data Elements (CDEs) and analytical tools for the interpretation of data, and instruments for checking uniformity, consistency, accuracy, timeliness, reproducibility, and privacy of the data. Headquarters: The institution of the Chair of the SC serves as the Headquarters of the Network. The Chair of the SC can be any PI involved in the Network. The Chair serves as the PI of the Headquarters and awards and implements the scientific, operational, and organizational policies of the Network. The headquarters provides the executive leadership, scientific direction, and management for the Network. It serves as a center for information dissemination to investigators and institutions in the Network as well as to others outside the Network. Funds: Funds will reside with 1) the individually funded U01 awardees in the Network, and 2) the Headquarters. The PI will have funds available through the individual U01 awards to support the development of the scientific program and clinical protocols. All investigators will be encouraged to seek supplemental funding through the Small Business Innovation Award (SBIR, R43 and/or R44), Small Business Technology Transfer (STTR, R41 and/or R42), Exploratory/Developmental grants (R21/R33), and other research support mechanisms. Core Funds for the Headquarters: Core Funds will be available to the Chair of the SC. Applicants under this RFA should not apply for the Core Funds in their U01 applications. Core Funds are reserved for post-award collaborative research and for a variety of other functions: 1. Core Funds are used to expand participation within the Network through supplemental funding to an investigator who is not part of the Network. However, receipt of these supplemental funds does not, in and of itself, imply membership in the Network or on the SC. 2. Core Funds are used for moving a new marker test to the point at which it can be validated at multiple centers and in larger populations. Test reagents will require scale-up at this point, and the SC will require sufficient funding to contract to commercial laboratories or companies that can scale up production and maintain quality of the reagents (i.e., monoclonal antibodies, labels, etc.) and to Clinical Epidemiology and Validation Centers for subject accrual. Core Funds will also be used for data management, travel, meetings, and other collaborative activities of the Network. Supplements from the Core Funds will provide direct costs and appropriate facilities and administrative costs. The following example illustrates the functions of the Network and the support it offers for moving basic research findings into clinical practice: An investigator within the Network identifies a putative biomarker through original laboratory research. Based on the pilot research findings, the putative marker seems to be useful for early cancer detection. The investigator can then approach the SC for additional evaluation of the marker and possible support for further testing. The SC then has the responsibility to review the data on the potential marker using its standing formal criteria as a guide. The SC can consult the Advisory Committee to obtain information on the requirements and need for additional research on the marker. It also can consult the BRL and the Clinical Centers regarding requirements for laboratory tests, needs for quality assurance, and the availability of patient groups for clinical validation. If necessary, scientific resources from other Centers can be pooled to conduct studies. Concurrently, the informatics team in the DMCC can develop tools for the analysis of results. There is also flexibility so that investigators outside the Network can form collaboration(s) with one of the existing centers, or directly bring their discoveries to the SC (i.e., by Letter-of-Intent). To support such efforts, the SC is able to use Core Funds to supplement the investigator’s ongoing research. The investigator, in turn, must agree to share his research findings and become part of the Network as an associate member. Recipients of Core Funds, such as commercial laboratories or manufacturing companies and institutions of outside investigators, participating for example in validation studies, will be subjected to the resource sharing and intellectual property requirements set forth in Section 3 of the Supplemental Instructions of this RFA. Awardees must advise Core Funds recipients and outside investigators of these requirements. C. Objectives (applicable to Network as a Whole) As described in the original RFA (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-98-028.html), the goals of the Network are to discover, develop, and evaluate biomarkers/reagents (Phases I-III) for the earlier detection of cancer and for the assessment of risk for developing cancer. The intent of this RFA is to continue to foster research investigations, technological innovations, and collaborations to accelerate the development of biomarkers and tools that have the potential of rapidly moving to Phase II and Phase III. Specifically, the objectives of the Network include: o the development and testing of promising biomarkers or technologies at institutions with the necessary scientific and clinical expertise, to obtain preliminary information to guide further testing; o the timely and early phase evaluation of promising, analytically-validated biomarkers or technologies, these evaluations would include measures of diagnostic predictive accuracy, sensitivity, specificity, and, whenever possible, medical benefits, such as predictors of clinical outcome or surrogate endpoints for early detection and for prevention intervention clinical trials; o the timely development of biomarker expression patterns, sometimes of multiple markers simultaneously, which will serve as background information for subsequent large definitive validation studies in the field of cancer detection and screening; o collaboration among academic and industrial leaders in molecular biology, molecular genetics, proteomics, clinical oncology, computer science, public health, and other areas to facilitate the development of high-throughput, sensitive assay methods to identify biomarkers that are useful in detecting cancer in its early stages and in assessing cancer risk; o the conduct of the sequential early phases of clinical/ epidemiological studies, (i.e., cross-sectional, retrospective; Phase I-III as described above), to evaluate predictive value of biomarkers; and o encouragement of collaboration and rapid dissemination of information among awardees to ensure progress and avoid fragmentation of effort. Because early detection and treatment issues are often related, the Network seeks meaningful participation from various medical organizations. In some of its activities, the Network may need to relate programmatically to research infrastructures supported by NCI (e.g., Specialized Programs of Research Excellence [SPOREs](http://spores.nci.nih.gov/), Cancer Genetics Network [CGN] (http://epi.grants.cancer.gov/CGN/), Breast and Colon Cancer Family Registries (http://epi.grants.cancer.gov/CCFR/index.html and http://epi.grants.cancer.gov/BCFR/index.html), Cooperative Human Tissue Network (http://www-chtn.ims.nci.nih.gov/), Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/), with ongoing NCI clinical research programs/trials (e.g., Clinical Community Oncology Program [CCOP](http://www3.cancer.gov/prevention/ccop/), Prostate, Lung, Colon, and Ovarian Trial [PLCO]) (http://www3.cancer.gov/prevention/plco/index.html); or with other health agencies, such as the Food and Drug Administration (FDA), the Department of Defense (DOD), and the Veteran’s Administration (VA). Certain types of trials in earlier detection, especially those involving treatment, may best be conducted as inter-group studies with treatment-oriented cooperative groups, such as the NCI Clinical Cooperative Groups, NCI designated Cancer Centers, international collaborators, clinical epidemiologists, and health maintenance organizations. The NCI anticipates that augmenting the EDRN expertise with a broad base of clinical and public health perspectives will enable the Network to apply existing methods and newly discovered technologies toward clinical application. D: Scope (applies to this RFA) The scope of this RFA is to establish and enhance the BDL which form one of the four scientific components within the Network. In the context of this RFA, development will encompass correlative study to further develop and validate biomarkers initially identified or characterized by applicants themselves or by other investigators in accordance with the Phase I and Phase II of the Biomarker Development Guidelines (Pepe et. al., 2001). The BDL will conduct translational research in the biology of incipient neoplasia encompassing the development, characterization and testing of biomarkers of early cancer or risk, development of relevant technologies for biomarker detection, and analytical tools for the evaluation of biomarkers. Translational research in this context is defined as the movement of discoveries from the laboratories into patient or population research settings or the movement of observations from patient settings back to the laboratory. Major components of this process are to standardize assays and to develop methods of analytic quality control. The NCI has identified the following high-priority research opportunities in early detection and risk assessment (for details see section ADVANCING DISCOVERY AND ITS APPLICATION in the Plans and Priorities for Cancer Research [http://plan.cancer.gov/]): o Determine secreted proteins and other molecular signatures that correlate with the presence of pre-cancerous and cancerous lesions; o Develop highly sensitive and specific assays to detect cancer-related proteins in body fluids; o Develop highly specific and sensitive assays to detect tumor cells in body fluids; and o Develop highly specific and sensitive assays to detect molecular products of tumor cells in body fluids with emphasis on the identification of molecular determinants (risk factors) in accessible surrogate anatomic sites for the less accessible major cancer sites This RFA encourages the submission of applications in broad categories of translational studies on complex cellular pathways, processes, and networks to identify the molecular and cellular signatures of cells which can be used for earlier detection or for risk assessment. Special emphasis should be placed on cancers of common occurrence, such as prostate, breast, colon, lung, ovary, upper-respiratory tract, pancreatic; and other less prevalent epithelial cancers, which are the major causes of cancer-related mortality and have yet to be controlled with screening and prevention. These activities may include, but are not limited to: I. Development of comprehensive panels of biomarkers/methods to identify molecular changes, i.e., gene mutations, changes in gene and protein expressions, and epigenetic changes associated with early stages of cancer. o Identification and evaluation of molecular fingerprints/expression profiles of genomic, proteomic, and epigenetic alterations in tissue and body fluids, i.e., sputum, urine, pancreatic juices, serum, and plasma; o Development of panels of biomarkers that can effectively identify early disease phenotypes or pre-cancerous lesions involving abnormalities in many biological processes; o Determination of secreted proteins and protein profiles that correlate with the presence of pre-cancerous and cancerous lesions; o Identification and evaluation of molecular, genetic, and cytologic markers of the risk of impending cancer; and o Determination of membrane and membrane-associated proteins and profiles, and other macromolecules that correlate with the presence of pre-cancerous and cancerous lesions. II. Identification and evaluation of molecular profiles for risk stratification by improving pathological classification of early lesions. Expand marker identification to predict early stages of disease and risk of recurrence. o Development of molecular markers that can augment or replace tissue-based assays. o Development of markers/methods to improve current methods or modalities of detection. III. Development of highly specific and sensitive assays/biomarkers to detect molecular alterations in circulating nucleic acids and cells in body fluids, including serum and plasma. o Development of reagents/biomarkers to detect cancer-specific signatures that may signal the presence of small numbers of premalignant cells. IV. Development of highly specific and sensitive markers to detect molecular products of tumor cells in body fluids with emphasis on the identification of molecular determinants in accessible surrogate anatomic sites for the less accessible major cancer sites. V. Study of molecular signatures to identify risk and early stage disease due to infectious agents, pathogens, and other environmental agents. Other approaches for the development of biomarkers for early detection of cancer and identification of cancer risk will be accepted as well. However, the application should clearly delineate the time-line for biomarkers development from Phase I, to Phase II and to Phase III. Decision criteria should be developed to triage biomarkers that are not relevant to identification of risk and detection of cancer at earlier stages. The search for new markers should reflect new information about key points in cancer biology (i.e., molecular pathogenesis, apoptosis, cell cycle control). However, this RFA will not support research of a fundamental nature, such as studies on growth regulation, cell cycle control, or other basic studies that are not explicitly focused on early detection and risk identification in humans. To expedite clinical application, the validation of the biomarkers will be performed in collaboration with the other scientific components of the Network. For discovery of technology and molecular tools, applicants are encouraged to develop collaboration with investigators participating in various NCI-sponsored programs, such as the Innovative Molecular Analysis Technology (IMAT) (http://otir.nci.nih.gov/tech/imat.html), and Unconventional Innovative Program (UIP)(http://otir.nci.nih.gov/tech/uip.html). Some of the emerging technologies, such as nanotechnology, could offer important new tools for detection where existing and more conventional technologies may be reaching their limits. Applications employing nanotechnology to provide direct readout of genomic, proteomic, and epigenomic information both at the single cell and single molecule level are encouraged. Applicants must advise any collaborating SPOREs, IMAT, or UIP investigators that, with respect to these collaborations, their institutions will be subject to the resource sharing and intellectual property requirements set forth in Section 3 of the Supplemental Instructions of this RFA. MECHANISM OF SUPPORT This RFA will use the NIH Cooperative Agreement (U01) award mechanism. As an applicant, you will be primarily responsible for planning, directing, and executing the proposed project. The anticipated award date is July 1, 2005. Applications that are not funded in the competition described in this RFA may be resubmitted as NEW investigator-initiated applications using the standard receipt dates for NEW applications described in the instructions to the PHS 398 application. The RFA may be reissued in the future, contingent upon the availability of funds. This RFA uses just-in-time concepts. It also uses the non-modular budgeting formats (see http://grants.nih.gov/grants/funding/modular/modular.htm). Follow the instructions for non-modular budget research grant applications. This program does not require cost sharing as defined in the current NIH Grants Policy Statement at http://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm. The NIH (U01) is a cooperative agreement award mechanism. In the cooperative agreement mechanism, the Principal Investigator retains the primary responsibility and dominant role for planning, directing, and executing the proposed project, with NIH Program Coordinator being substantially involved as a partner with the Principal Investigator, as described under the section "Cooperative Agreement Terms and Conditions of Award.” At this time the NCI anticipates that there will be a renewed competition after 5 years. If the NCI does not continue the program, awardees may submit grant applications through the usual investigator-initiated grants program. However, before submitting such an application, applicants are advised to contact Program Coordinator listed under the WHERE TO SEND INQUIRIES section listed below. FUNDS AVAILABLE The NCI intends to commit approximately $3 million in FY 2005 to fund five-six new and/or competing continuation grants in response to this RFA. An applicant may request a project period of up to 5 years. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the NCI provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. At this time, the NCI has not determined whether or how this solicitation will be continued beyond the present RFA and related RFAs for the Network. ELIGIBLE INSTITUTIONS You may submit (an) application(s) if your institution has any of the following characteristics: o For-profit or non-profit organizations o Public or private institutions, such as universities, colleges, hospitals, and laboratories o Units of State and local governments o Eligible agencies of the Federal government o Domestic or foreign institutions/organizations o Faith-based or community-based organizations. Domestic institutions may propose collaborations/consortia with foreign institutions and vice versa. For this RFA, teams composed of NIH intramural investigators may submit project applications to become components of the Network, but they may not request or receive funds from this program. The intramural applicant will not compete for extramural funds (http://deaintranet.nci.nih.gov/ncipolicy/final-intramural-pi.htm) INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. The NCI encourages applications from extramural and NIH intramural scientists with broad expertise in the biology of cancer detection and risk assessment. Researchers in NIH intramural laboratories may submit applications. However, they may not receive salary, equipment, supplies, or other remuneration from the extramural RFA set-aside funds for this program. An NIH intramural PI must obtain the approval of her/his NIH Scientific Director, or a designated official to allocate resources to the project, and must follow both the general application format instructions and the additional guidelines for NIH intramural project applications under "ADDITIONAL INSTRUCTIONS." NIH intramural project applications will be reviewed and scored with the U01 applications. The NIH intramural projects selected by the NCI to be components of the EDRN will participate in a manner that is analogous to the U01 awardees. SPECIAL REQUIREMENTS Definitions Awardee: The institution to which a cooperative agreement (U01) is awarded. Principal Investigator (PI): The investigator who is designated by the applicant organization to direct the project to be supported by the U01 grant or NIH intramural project in response to the RFA. The PI will assume the responsibility and accountability to the applicant organization officials and to the NCI for the performance and the proper conduct of the research supported by the U01 mechanism or the NIH intramural project in accordance with the terms and conditions that are stated in the RFA. The PI will be a voting member of the SC. NCI Program Director: A health scientist administrator from the NCI extramural staff will provide normal stewardship for the U01 grants awardees. NCI Program Coordinator: A health scientist administrator from the NCI extramural staff, the Program Coordinator will be substantially involved in the scientific coordination and collaboration within the Network, will have responsibilities in broad scientific and programmatic issues, and will serve as a voting member of the SC, as defined under the “Cooperative Agreement Terms and Conditions of Award.” Cooperative Agreement Terms and Conditions of Award These special Terms of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines; DHHS Grant Administration Regulations at 45 CFR Parts 74 and 92, and other; DHHS, PHS, and NIH Grant Administration policy statements. (Part 92 applies when state and local governments are eligible to apply as a "domestic organization.") For NIH Intramural Projects, these terms and conditions will be provided to the PI of the NIH Intramural Project and the NIH Institute Scientific Director at the time of selection to be a Network component. Under the cooperative agreement, the NCI purpose is to support and/or stimulate the recipient's activity by involvement in and otherwise working jointly with the award recipient in a partner role, but it is not to assume direction, prime responsibility, or a dominant role in the activity. Consistent with this concept, the dominant role and prime responsibility for the activity resides with the awardee(s) for the project as a whole, although specific tasks and activities in carrying out the studies will be shared among the awardees and the NCI Program Coordinator. A. Awardee Rights and Responsibilities: Extramural and NIH Intramural Projects The PI of a U01 or NIH intramural project will have the primary authority and responsibility to define objectives and approaches, including research design and protocol development; participant recruitment and follow-up, if applicable, data collection, quality control, interim data and safety monitoring, and to plan, conduct, analyze, and publish results. The PI of a U01 or NIH intramural project will assume responsibility for managing individual protocols/research and collaborative projects approved by the Steering Committee. The PI of a U01 or NIH intramural project will assume responsibility and accountability to the applicant organization officials and to the NCI for the performance and proper conduct of the research supported by the U01 or the NIH intramural project in accordance with the terms and conditions of the award. The PI of a U01 or NIH intramural project will serve as a voting member of the steering committee will attend the Planning meeting and two Steering Committee meetings in the first year and two Steering Committee meetings per year and the EDRN-Sponsored Gordon Conference every 18 months in subsequent years. The attendance of PI at these meetings is considered an essential part of the grant. The PI of a U01 or NIH intramural project will be responsible for accepting and implementing the goals, priorities, common protocols, procedures, and policies agreed upon by the Steering Committee. The PI of a U01 or NIH intramural project will retain custody of and have primary rights to the data developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies. The PI of a U01 or NIH intramural project will be responsible for collaborating on common research designs or protocols, including methods and requirements for joint participation and collaboration as directed by the Steering Committee, and handling of data, including appropriate sharing of methods and data among collaborating organizations and submission of protocols to DMCC. Network Collaborative Studies: The PI of a U01 or NIH intramural project will be responsible for accepting and implementing the goals, priorities, common protocols, procedures, and policies agreed upon by the Steering Committee for the Network collaborative studies. In some cases, the PI may be asked to serve as a lead investigator for the Network collaborative studies. The PI of a U01 or NIH intramural project will ensure Network and NCI review and approval of protocol, concepts, final protocol documents, informed consents, and study amendments, and advise NCI of changes in protocol status. The PI of a U01 or NIH intramural project will be responsible for collaborating on common research designs or protocols, including methods and requirements for joint participation and collaboration as recommended by the Steering Committee, and handling of data, including appropriate sharing of methods and data among collaborating organizations. The PI of a U01 or NIH intramural project will be responsible for accruing subjects on collaborative studies approved by the Steering Committee. B. NCI Extramural Staff Responsibilities There will be only one NCI Program Coordinator for the Network. However, the Program Coordinator may be assisted by other NCI Program Directors and Staff on specific scientific issues as needed. The NCI Program Coordinator will have substantial scientific programmatic involvement during conduct of this activity, through technical assistance, initiation of Network collaborative projects, data sharing and analysis, composition of reports, and advice and coordination above and beyond normal program stewardship for grants as described below. Because of the Network’s diverse research agenda and the number of tasks that have to be accomplished to achieve its goals, a number of NCI staff members may interact with the Network as needed. The NCI Program Coordinator (a staff member in the Division of Cancer Prevention) will assist the Network on scientific and programmatic issues and well advise the Network on the availability of other resources. A member from the Chemoprevention Branch, NCI, will be available to assist the Network on intermediate endpoints and on any ongoing chemoprevention trials relevant to the Network studies. A member from the Biometry Branch, NCI, will be available to assist the Network on the issues of study design, sample size, and other statistical computations. The other NCI staff may assist and advise the Network on relevant programmatic and scientific issues through the NCI Program Coordinator. The Program Coordinator will convene the initial meeting of the SC, have voting membership on the SC, and, as determined by that committee, its subcommittees. Although the PI will have lead responsibilities in all collaborative tasks and activities, it is anticipated that the NCI Program Coordinator will have lead responsibilities in managing and sharing the broad programmatic issues among awardees. An NCI Program Director designated in the Notice of Grant Award will be responsible for normal programmatic stewardship and monitoring of the awards. The NCI Program Coordinator will identify other participating NCI staff. The NCI Program Director may also serve as the NCI Program Coordinator. The NCI reserves the right to adjust funding, withhold support, suspend, terminate, or curtail the study or an individual award in the event of a failure to comply with the Terms and Conditions of Award, substantial shortfall in participant recruitment, follow-up, data reporting, quality control, or other major breach of the protocol, or human subject ethical issues, whenever applicable. C. Collaborative Responsibilities 1. Steering Committee (SC): The SC will have major scientific management oversight and responsibility for developing collaborative research designs, protocols and manuals, facilitating the conduct and monitoring of studies, and reporting study results. The SC will be composed of the PIs from each member component (i.e., U01 or Intramural research project) of the Network, the Principal Investigator of the DMCC, and the NCI Program Coordinator. Each member component will have one vote. The Chair (non-NIH person) will be selected by the Steering Committee. The institution of the Chair of the SC will serve as the Headquarters (for definition, see Network Organization). Subcommittees, including the existing ones, will be established/maintained by the SC, as it deems appropriate; the NCI Program Coordinator will serve on subcommittees as he/she deems appropriate. After all the Network components have been funded, the SC will convene. Responsibilities of the SC include, but are not limited to o updating and refining established Network policies and procedures; o updating and refining established policies and procedures for collaborative projects, protocols, and Network-defined projects; o updating and refining established policies and procedures for reviewing changes in projects not showing translational significance at the request of the laboratories/centers, and making recommendations to the NCI for replacing the project with more promising ones with revised scope and adjusted budget (increase in the budget will not be permitted); o updating and refining established standards or “decision criteria” for validating biomarkers/reagents for further clinical studies, such as testing early detection strategies, or as risk factors; and o updating and refining established policies and procedures for accepting, reviewing, and recommending proposals from investigators outside the Network for supplemental funding and expanding the Network participation; Investigators are encouraged to review the EDRN Manual of Operation) (http://www3.cancer.gov/prevention/cbrg/edrn/organization.html#manual) 2. The SC will establish Data and Safety Monitoring Committee (DSMC) for clinical trials as appropriate to ensure protection of human subjects. 3. The SC will review patient accrual, follow-up, protocol compliance, results of audits, and regulatory requirements at the participating Centers and formally report the results of its reviews to the NCI. 4. The SC will promote and foster the inclusion of women and ethnic minorities in clinical studies and assure the completeness of informed consent. 5. The Committee will track the Network research progress and assure that the results of laboratory research and clinical studies are published in peer- reviewed journals in a timely manner and in accordance with the publication policies of the Network. At any time during a Network project, the SC may ask BDLs or CEVCs to serve as a BRL on an as needed basis. The SC may also examine the validation data for biomarkers/reagents developed by the Network, and decide when a biomarker is sufficiently validated, or recommend when to stop non-productive experiments relating to biomarker validation. 6. The SC will discuss collaborative projects to be pursued jointly with the funds set aside from the Headquarters and from individual U01 awardees, or NIH intramural project budgets. 7. Collaborative studies/protocols will be approved by the Steering Committee. Data will be submitted centrally to the DMCC. The SC will define the rules regarding access to data and publications consistent with NCI policies. 8. The SC will plan one of several workshops during the Network project period to inform the scientific community and relevant advocacy groups of the progress made toward development and clinical application of biomarkers developed through the Network. The NCI Program Coordinator, the Network Advisory Committee, and other NCI staff will provide the SC with advice on participants for the workshops and symposia. The Data Management and Coordinating Center will manage the logistics for these meetings. 9. The Steering Committee or its Executive Committee in consultation with the NCI will determine the PI of the Network-wide validation study. Network Consulting Committee: 1. A Network Consulting Committee (NCC) was established by the NCI. The NCC advises the SC through the NCI on relevant scientific issues, including study design, prioritization of biomarker development, development of collaborative study protocols, including decision criteria for clinical applications, i.e., early detection, prognosis, etc. 2. The membership to the Committee and duration of service was established by the NCI in consultation with the Steering Committee. The membership includes members/institutions not participating in the Network. The NCC includes basic scientists, clinicians, prevention scientists, epidemiologists, ethicists, statisticians, and members from relevant advocacy groups. Scientific experts were drawn from various disciplines relevant to multi-center detection research and experts in data management, biostatistics, and clinical study design. 3. The Chair of the NCC is elected by its members. The Chair of the SC also serves as a member of the advisory committee. The NCI is represented by relevant program staff. 4. The NCC evaluates the progress and success of the Network against the criteria developed by the Steering Committee. 5. The NCC helps the NCI in site visits to the participating institutions, as necessary. 6. The NCC collaborates with the SC to suggest participants for and to assist in the implementation the workshops and symposia and to provide liaison between the cancer research community and the Network. Data Safety and Monitoring Committee: The Data Safety and Monitoring Committee (DSMC) will be appointed by and report to the Steering Committee in consultation with the EDRN Network Consulting Committee and the Division Director. The DSMC will be composed of external, non-participating scientists appointed by the Steering Committee to monitor patient safety, conduct data audits, and document progress to the NCI Program Director and the Advisory Committee. DSMC’s policy must be in compliance with the NCI DSM policies at http://cancer.gov/clinicaltrials/conducting/dsm-guidelines D. Arbitration A panel that is formed to review any scientific or programmatic disagreement (within the scope of the U01 award or the NIH intramural project), between U01 awardees or NIH intramural projects and the NCI. The panel will be composed of three members: one selected by the SC (with the NCI Program Coordinator not voting), or by an individual U01 awardee or NIH intramural project in the event of an individual disagreement; a second member selected by the NCI; and, the third member selected by the two prior selected members. Any disagreement that may arise on scientific/programmatic matters (within the scope of the award), between award recipients and the NCI may be brought to arbitration. This special arbitration procedure in no way affects the awardee's right to appeal an adverse action that is otherwise appealable in accordance with the PHS regulations at 42 CFR Part 50, Subpart D and DHHS regulation at 45 CFR Part 16. WHERE TO SEND INQUIRIES We encourage inquiries concerning this RFA and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into 4 areas: scientific, technology, peer review, and financial or grants management issues: o Direct your scientific questions for this RFA to: Sudhir Srivastava, Ph.D., M.P.H. Program Coordinator Division of Cancer Prevention National Cancer Institute 6130 Executive Boulevard, EPN Room 3142 Bethesda, MD 20892 Rockville, MD 20852 (for express/courier service) Telephone: (301) 435-1594 FAX: (301) 402-8990 Email: firstname.lastname@example.org o Direct questions about intellectual property, technology licensing, data sharing, and research tools issues for this RFA to: Wendy E. Patterson, Esq. National Cancer Institute Technology Transfer Branch 6120 Executive Boulevard, EPS Room 450 Bethesda, MD 20892-7182 Rockville, MD 20852 (for express/courier service) Telephone: (301) 435-3110 FAX: (301) 402-2117 Email: email@example.com o Direct questions about peer review issues for this RFA to: Referral Officer National Cancer Institute Division of Extramural Activities 6116 Executive Boulevard, Room 8041, MSC 8329 Bethesda, MD 20892-8329 Rockville, MD 20852 (for express/courier service) Telephone: (301) 496-3428 FAX: (301) 402-0275 Email: firstname.lastname@example.org o Direct questions about grants management matters for this RFA to: Karen Chuang Grants Administration Branch National Cancer Institute 6120 Executive Boulevard, EPS Room 243 Bethesda, MD 20892 Rockville, MD 20852 (for express/courier service) Telephone: (301) 496-2784 FAX: (301) 496-8601 Email: email@example.com LETTER OF INTENT Prospective applicants are asked to submit a letter-of-intent that includes the following information: o Descriptive title of the proposed research o Name, address, and telephone number of the Principal Investigator o Names of other key personnel o Participating institutions o Number and title of this RFA Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NCI staff to estimate the potential review workload and plan the review. The letter of intent is to be sent by the date listed at the beginning of this document. The letter-of-intent should be sent to: Sudhir Srivastava, Ph.D., M.P.H. Division of Cancer Prevention National Cancer Institute 6130 Executive Boulevard, EPN Room 3142 Bethesda, MD 20892 Rockville, MD 20852 (for express/courier service) Telephone: (301) 435-1594 FAX: (301)402-8990 Email: firstname.lastname@example.org PRE-SUBMISSION MEETING It is also the intent of the program to hold a pre-submission meeting on November 3, 2004, in Bethesda, MD, with the potential applicants prior to the letter of intent deadline. SUBMITTING AN APPLICATION Applications must be prepared using the PHS 398 research grant application instructions and forms (rev. 5/2001). Applications must have a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the Universal Identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling (866) 705-5711 or through the web site at http://www.dunandbradstreet.com/. The D&B number should be entered on line 11 of the face page of the PHS 398 form. The PHS 398 document is available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance, contact GrantsInfo, Telephone: (301) 435-0714; Email: GrantsInfo@nih.gov. SUPPLEMENTARY INSTRUCTIONS: Special Instructions for Preparation of the Application To promote the development of a collaborative program among the award recipients, a number of issues need to be addressed in the application as discussed below. For U01 and NIH intramural applicants to this RFA, only the "Research Plan" section of the PHS 398 grant application is changed. The remainder of the PHS 398 application form remains the same. The "Research Plan", sections a to d are altered as follows. (The subsequent sections e. to i. remain the same) o The number of pages is increased from 25 to 35 pages; the 35-page limitation applies to the replacement for sections a to d only, and does not include the pages for sections e to i. o The 35 pages should be apportioned as desired by the applicant to cover new sections 1 to 3 that replace sections a to d. The three sections are: 1. Applicant; 2. Scope of Research; and, 3. Collaborations. Section 1 – Applicant. Applicants should briefly state the major objectives of the project and describe what expertise the group encompasses, as well as specialized or unique facilities, core resources, and services that are available to support these objectives. In this section, applicants should describe any ongoing grant-supported, institutional, or private sector resources that augment or complement resources for which funding from this RFA is sought. The roles of all key personnel, collaborators, and consultants who are associated with the application may be briefly described; however, the full extent of activities for each participant should be covered in Section 2. Section 2 – Scope of Research. For competing renewal applicants, Section 2 should have a description of the goals of the previous grant and include the scientific progress from the previous project period. Indicate the status of developed markers according to the biomarker developmental phases (Pepe et. al., 2001). For all applicants, depending on the composition and structure of the group, this section may be organized as distinct projects or as one integrated plan; in either case, the page limitation is the same. There is no requirement for applicants to use the format of an R01 application. Instead, applicants should define the major research questions and opportunities related to objectives of EDRN that their group effort proposes to undertake. Applicants should describe the approaches to be taken by the group in the aggregate or as inter-dependent projects, and should describe the rationale for approaches to be used or planned for development. Applicants are encouraged to use this section of the application to highlight how the diverse expertise of the group members contributes to the innovation of which the group is capable, the flexibility they possess to redirect research when scientific progress warrants it, and their ability to anticipate new directions, based on their individual experience and ability to contribute to a collective effort. The roles and expertise of all key personnel, collaborators, and consultants who are associated with the application should be documented; letters from collaborators and consultants should be included in Section 1 of the research plan format as specified in the instructions for the Form PHS398 application. Applicants should list and summarize each of the agreements with industry collaborators, including a description of the materials, technologies and/or expertise to be provided by such collaborators. Detailed documentation of license agreement(s), intellectual property arrangements, and data sharing concerning the proposed or existing collaboration with industrial partner(s) will be requested as appropriate if an applicant is selected for consideration for funding. These documents must be submitted by the Institutional Technology Transfer Office. Section 3 – Collaborations. For competing renewal applications, applicants should describe their participation in the EDRN activities, and the contributions in terms of collaborations within, and outside the Network in meeting the EDRN missions (see EDRN Second Report, http://www3.cancer.gov/prevention/cbrg/edrn/edrn_report2002.pdf, Metrics for Programmatic Evaluation). For competing renewal, applicants are also required to list all approved collaborative studies by the EDRN Executive Committee. Letter of approval or the minutes of the EDRN Executive Committee indicating the approval should included in Appendix. For new applications, applicants should describe the experience of their group in collaborative programs and activities with academic and industry partners. Some examples of collaborations that may be provided in support of the application are listed below: o demonstrated evidence of collaborative projects and publications; o demonstrated evidence of collaborative funding; and o sharing of data and resources, e.g., specimens, technology, research protocols. The collaborative requirements are integral to EDRN activities and applications will be judged for their scientific merits of the collaborative study, not just the individual study. Applicants must highlight, whenever possible, the collaborative component in the study with justifications as to why collaboration is needed and how this would add value to their proposed study as opposed to individual study? Applications should describe their plans for any future collaborations for the proposed EDRN biomarker studies, both within and outside Network. These plans could include other collaborative projects that they are currently involved in, or plan to develop with any NCI-sponsored programs, such as SPORE or Cooperative Groups. o In Section 3, applicants must include their specific plans for responding to the "Cooperative Agreement Terms and Conditions of Award" section. Applicants should state their willingness to collaborate and share data freely with the other EDRN components, to participate in planning and attending workshops and symposia, to serve on the SC and be bound by its decisions, and to be able and willing to share data and research resources with each other and the NCI. Successful applicants will be expected to submit (on-line) information on specimen collections per the Network’s Common Data Elements and register their protocols with the Network’s DMCC. o At the end of Section 3, applicants must append a letter from the applicant institution describing how that institution intends to meet the NIH policies for sharing of data or why data sharing is not possible. In this regard, attention is drawn to the NIH Final Statement on Sharing Research Data (http://grants.nih.gov/grants/policy/data_sharing/index.htm and http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html), which was published in the NIH Guide on February 26, 2003. This is an extension of NIH policy on sharing research resources, and reaffirms NIH support for the concept of data sharing. The new policy becomes effective with the October 1, 2003 receipt date for applications or proposals to NIH. Investigators submitting an NIH application will be required to include a plan for data sharing or to state why data sharing is not possible. o Applicants to this RFA must also include a research tools and resources sharing plan in the letter to be appended to Section 3. Investigators conducting biomedical research frequently develop unique research resources. The policy of the NIH is to make available to the public the results and accomplishments of the activities that it funds. NIH recognizes that certain research activities may result in inventions and that grantees are entitled to protect such inventions through patenting and licensing activities in accordance with the Bayh-Dole Act, 35 USC § 200 et seq. and the implementing regulations, 37 CFR Part 401 (“Bayh-Dole Act”). However, the EDRN’s core mission of collaboration both between Network members and between Network members and third party industry partners necessarily anticipates the sharing of intellectual property arising out of research resources developed in Network-related activities. To address the interest in assuring that research resources are accessible, NIH requires applicants who respond to this RFA to submit a plan (1) for sharing the unique research resources, e.g., human biospecimens and novel cancer biomarkers, generated through the grant; and (2) addressing how they will exercise intellectual property rights (described below), should any be generated through this grant, while making such research resources available to the broader scientific community. The sharing of research resources and intellectual property plans must make unique research resources readily available for research purposes to qualified individuals within the scientific community in accordance with the NIH Grants Policy Statement (http://grants.nih.gov/grants/policy/nihgps/) and the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice, December 1999 (http://www.ott.nih.gov/policy/rt_guide_final.html and http://ott.od.nih.gov/NewPages/64FR72090.pdf)(“NIH Research Tools Guidelines”). These documents also define terms, parties, responsibilities, prescribe the order of disposition of rights, prescribe a chronology of reporting requirements, and delineate the basis for and extent of government actions to retain rights. Patent rights clauses may be found at 37 CFR Part 401.14 and are accessible from the Interagency Edison web page (http://www.iedison.gov); see also, 35 USC § 210(c); Executive Order 12591, 52 FR 13414 (Apr. 10, 1987); and Memorandum on Government Patent Policy (Feb. 18, 1983). If applicant investigators plan to collaborate with third parties, the research tools sharing plan must explain how such collaborations will not restrict their ability to share research materials produced with NIH funding. NCI believes that applicants can satisfy the requirement to submit the research resources plan and intellectual property plan in a number of ways. GUIDANCE FOR PREPARATION OF RESEARCH RESOURCES PLAN AND INTELLECTUAL PROPERTY PLAN The EDRN is premised on the belief that an established integrated, multi- disciplinary environment will expedite clinical applications of biomarker research. Comprised of 31 principal members, the EDRN is organized in four components: 18 BDLs, three BVLs, nine CEVCs, and one DMCC. From the outset, the NCI anticipated that EDRN members would collaborate with industry both to develop biomarkers and/or reagents and to provide a clinical environment for the evaluation of new technologies. Early interactions with industry are expected to permit research collaborations likely to benefit both EDRN grantees and industry partners. It is hoped that validated biomarkers may ultimately be commercialized into diagnostic products for early detection of cancer and cancer risk. Many of the EDRN investigators have had active collaborations with industry. While the one university/one company collaborations have worked well, there is general agreement that successful multi-institution/company collaborations have been harder to implement. Restricted availability of unique research resources, upon which further studies are dependent, can impede the advancement of research. The NIH is interested in ensuring that the research resources developed through this grant also become readily available to the broader research community in a timely manner for further research, development, and application, in the expectation that this will lead to products and knowledge of benefit to the public health. Investigators conducting biomedical research frequently develop unique research resources. The policy of the NIH is to make available to the public the results and accomplishments of the activities that it funds. To address this interest in assuring research resources are accessible, NIH requires applicants who respond to this RFA to submit a plan: (1) for sharing the research resources generated through the grant (e.g., human biospecimens and novel cancer biomarkers); and (2) addressing how they will exercise intellectual property rights, should any be generated through this grant, while making such research resources available to the broader scientific community consistent with this initiative. Therefore, the research resources tools sharing plan and intellectual property management plans must make unique research resources readily available for research purposes to qualified individuals within the scientific community in accordance with the NIH Grants Policy Statement (http://grants.nih.gov/grants/policy/nihgps/) and the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice, December 1999 (http://www.ott.nih.gov/policy/rt_guide_final.html and http://ott.od.nih.gov/NewPages/64FR72090.pdf)(“NIH Research Tools Policy”). These documents also: (1) define terms, parties, and responsibilities; (2) prescribe the order of disposition of rights and a chronology of reporting requirements: and (3) delineate the basis for and extent of government actions to retain rights. Patent rights clauses may be found at 37 CFR Part 401.14 and are accessible from the Interagency Edison web page, (http://www.iedison.gov); see also, 35 USC § 210(c); Executive Order 12591, 52 FR 13414 (Apr. 10, 1987); and Memorandum on Government Patent Policy (Feb. 18, 1983). If applicant investigators plan to collaborate with third parties, the research tools sharing plan must address how such collaborations will not restrict their ability to share research materials produced with NIH funding. NCI believes that applicants can satisfy the requirement to submit the research resources plan and intellectual property plan in a number of ways. Reviewers will comment, as appropriate, on the adequacy and feasibility of the sharing of research resources plan and the intellectual property plan. Comments on the plans and any concerns will be presented in an administrative note in the Summary Statement. These comments will not affect the priority score of the proposal. NIH program staff will consider the adequacy of the plans in determining whether to recommend an application for award. The approved plans will become a condition of the grant award and Progress Reports must contain information on activities for the sharing of research resources and intellectual property. Where it is anticipated that there will be an exchange of collections of human tissues, consideration should also be given to obtaining the appropriate assurances from the DHHS Office of Human Subject Protections (http://www.hhs.gov/ohrp/assurances/assurances_index.html) and necessary IRB approvals and/or exemptions. In addition, issues pertaining to the protection of patient identifiable information under the Privacy Rule of the Health Insurance Portability and Accountability Act of 1976 (HIPAA) should be addressed. For more information concerning the HIPAA Privacy Rule, see (http://www.hhs.gov/ocr/hipaa). In the development of the research resource sharing and intellectual property management plans, applicants should confer with their institutions’ office(s) responsible for handling technology transfer related matters and/or sponsored research. If applicants or their representatives require additional guidance in preparing these plans, they are encouraged to make further inquiries to the appropriate contacts listed above for such matters. Further, applicants may wish to independently research and review examples of approaches considered by other institutions such as those described on the NCI Technology Transfer Branch website (http://ttc.nci.nih.gov/intellectualproperty/). Budget: NOTE: NIH intramural project should supply the budget information and a composite budget as described below in “ADDITIONAL INSTRUCTIONS FOR NIH INTRAMURAL PROJECT APPLICANTS” for NIH Intramural Project Applicants. 1. Applicants must budget for travel and per diem expenses for SC meetings. In the first year, applicants should plan for two investigators, the principal investigator and an additional senior investigator, to attend a Planning Meeting and two SC meetings. In the second and subsequent years, applicants should plan for the PI and another investigator to attend two SC meetings per year. 2. Applicants must budget for travel and per diem expenses for participation in Network workshops and symposia. Applicants should plan that at least two investigators will attend a workshop or symposium every year. 3. Applicants must set aside 20 percent of their annual budgets or the actual amount of funds that was approved by the program staff for validation or any collaborative studies (applies to competing renewal applicant who is participating on ongoing validation studies) as follows: o The competing renewal applicant should set aside funds from the first year onward; and o The new applicant should set aside funds after the first year onward for Network collaborative studies. The use of these set-aside funds will be restricted and must be reviewed and approved by the Steering Committee and then recommended to, and approved by the NCI for release from the individual U01 awards. Indicate this amount in the Other Expenses category under the heading “Network Collaborative Funds.” 4. Applicants must budget for data collection on relevant common data elements (CDEs) for specimens during the course of study. For CDEs, please visit the EDRN web site http://www.cancer.gov/edrn. ADDITIONAL INSTRUCTIONS FOR NIH INTRAMURAL PROJECT APPLICANTS: NIH intramural project applicants must use the PHS 398 application form and the modified format and content described above with the following additional modifications. o On the Face Page, fill out only items 1., 2., 3. (leave item 3c. blank), 4., and 5. The remainder of the items should be left blank, AND THE APPLICATION MUST NOT BE SIGNED BY EITHER THE PI OR AN NIH INSTITUTE OFFICIAL. o Do not submit "Other Support," Checklist," "Personnel Report," or "Personal Data" pages. o The PI must obtain the approval of her/his NIH Institute Scientific Director for applying, for collaboration, for participating as a component of the EDRN under the terms and conditions of the RFA, and for complying with the policies of the Steering Committee. A copy of that letter of approval must be provided as part of a cover letter, addressed to the NCI Referral Officer, for the application. o The budget pages should supply the time and effort for each project participant, but no other budget figures should be included. The resources available for the project and the research environment should be carefully described, but no budget figures should be included. The NIH Institute Scientific Director, as part of the letter of approval for participation, must verify that appropriate intramural resources will be allocated to the project described in the application if it merits funding, and provide assurance that the conduct of the project will comply with the PHS regulations for research involving human subjects (if applicable), with the PHS policy on vertebrate animal research, and with the PHS policies for data sharing and access to research tools. USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001) application form must be affixed to the bottom of the face page of the application. Type the RFA number, CA-05-023 on the label. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title, THE EARLY DETECTION RESEARCH NETWORK: BIOMARKER DEVELOPMENTAL LABORATORIES, and number, RFA CA-05-023, must be typed on line 2 of the face page of the application form and the YES box must be marked. The RFA label is also available at http://grants.nih.gov/grants/funding/phs398/labels.pdf. SENDING AN APPLICATION TO THE NIH: For U01 applicants only (NIH intramural applicants must use the address in the Section below entitled "FOR NIH INTRAMURAL APPLICANTS"), submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: Center for Scientific Review National Institutes of Health 6701 Rockledge Drive, Room 1040, MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for express/courier service) At the time of submission, two additional copies of the application and all five copies of the appendix material must be sent to: Referral Officer Division of Extramural Activities National Cancer Institute 6116 Executive Blvd., Room 8041, MSC-8329 Rockville, MD 20852 (express courier) Bethesda MD 20892-8329 Telephone: (301) 496-3428 (for express/courier service) For NIH intramural Applicants: o Submit an unsigned, typewritten original of the application, and five photocopies to: Referral Officer Division of Extramural Activities National Cancer Institute 6116 Executive Blvd., Room 8041, MSC-8329 Rockville, MD 20852 (express courier) Bethesda MD 20892-8329 DO NOT send the application or any copies to the Center for Scientific Review. NIH intramural project applications must also be received by December 20, 2004. If an application is received after that date, it will be returned to the applicant without review. Appendices should be comprised of single-sided, unbound materials. APPLICATIONS HAND-DELIVERED BY INDIVIDUALS TO THE NATIONAL CANCER INSTITUTE WILL NO LONGER BE ACCEPTED. This policy does not apply to courier deliveries (i.e., FEDEX, UPS, DHL, etc.) (http://grants.nih.gov/grants/guide/notice-files/NOT-CA-02-002.html). This policy is similar to and consistent with the policy for applications addressed to Centers for Scientific Review as published in the NIH Guide Notice at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-012.html. APPLICATION PROCESSING: Applications must be received on or before the application receipt date, December 20, 2004, listed in the heading of this RFA. If an application is received after that date it will be returned to the applicant without review. Although there is no immediate acknowledgement of the receipt of an application, applicants are generally notified of the review and funding assignment within 8 weeks. The Center for Scientific Review (CSR) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. However, when a previously unfunded application, originally submitted as an investigator-initiated application, is to be submitted in response to an RFA, it is to be prepared as a NEW application. That is, the application for the RFA must not include an Introduction describing the changes and improvements made, and the text must not be marked to indicate the changes from the previous unfunded version of the application. Please note that amended applications will be accepted from the previous issuance of this RFA, CA-04-006, and responses to the reviewers critiques will be included. PEER REVIEW PROCESS Upon receipt, U01 applications will be reviewed for completeness by the CSR and for responsiveness by NCI program staff. NIH intramural project applications will be reviewed for completeness by the NCI Division of Extramural Activities, and for responsiveness by NCI program staff. Incomplete and/or non-responsive applications will not be reviewed. U01 and NIH intramural project applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities at the NCI in accordance with the review criteria stated below. As part of the initial merit review, all applications will: o Undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed and assigned a priority score o Receive a written critique o Receive a second level review by the National Cancer Advisory Board. REVIEW CRITERIA The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written comments, reviewers will be asked to evaluate the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. The scientific review group will address and consider each of these criteria in assigning the application’s overall score, weighting them as appropriate for each application. o Significance o Approach o Innovation o Investigator o Environment The application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. 1. Significance: o Does the proposed research convey the urgency of scientific needs in the area of biomarker-based diagnostics possible only through a consortium or a network approach? o Does the proposal uniquely discuss challenges and issues relevant to cancer detection and screening? o How would the proposed research complement or augment existing detection systems or methodologies? o What is the immediacy of the research opportunity in light of the EDRN- established phases of biomarker development for early detection of cancer and potentials for moving biomarkers to Phase II or Phase III in the next five years. (See “Research Objective: Background”). o To what extent are the specific aims integrated to address the proposed goals? o What is the potential impact of these studies, if successful? 2. Approach: o Are the conceptual framework, design, methods, and analyses adequately developed and appropriate to the aims of the project? o Has the applicant clearly defined their objective, hypothesis and scientific plan? o Does the applicant acknowledge potential problem areas and consider alternative tactics? o Can these approaches be used to derive biomarkers/reagents for a variety of malignant tumors? o Are the parameters, such as sensitivity, specificity, predictive value chosen to characterize the biomarkers/reagents sufficient and appropriate? o Are the study designs supported by adequate sample size and statistical reasoning? o Are the considerations given to minimize biases and reproducibility issues o in the proposed study design? o Are the criteria chosen to characterize biomarkers/reagents for early detection and/or risk assessment appropriate and adequate in light of the EDRN- established phases of biomarker development for early detection of cancer (See “Research Objective: Background”)? o Does the applicant have demonstratable evidence for bringing biomarkers to Phase II or Phase III? o Is the proposed approach or technology adaptable, or has the potential to analyze large samples in population setting for screening purposes? 3.Innovation: o Is the project original and innovative? o Does the project challenge existing paradigms or clinical practice? o Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area? o Will the approaches advance the field of biomarkers/reagents development in the context of cancer detection and risk assessment? 4. Investigators: o Are the principal investigator and collaborators appropriately trained and well suited to carry out this work? o Does the principal investigator have a track record of publishing papers relevant to cancer detection and risk identification? o Are the key personnel identified in the proposal experienced in cancer detection and prevention research? o To what extent do these investigators have the necessary complementary skills? o Have collaborations been established or consultants identified to provide the appropriate depth and breadth of scientific expertise required for the project? o Will this team of investigators contribute unique skills to the overall Network? 5. Environment: o Does the applicant have access to required human specimens, e.g. tissues, biological fluids, archived materials? o Does the applicant have access to pathology review and documentation of pathology report? o Does the applicant have the cooperation of surgeons and pathologists? o Does the applicant have access to normal tissues from the patients, and access to matched controlled specimens? o Are the facilities for experimentation appropriate to support the endeavor? o Does the scientific environment in which the work will be done contribute to the probability of success? o Do the proposed experiments take advantage of unique features of the institutional scientific environment and incorporate the best use of collaborative arrangements? o Is there evidence of institutional support? o Is there institutional support for computer services, including Internet access? o Has the applicant adequately addressed his/her institutional patent policy? ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following items will be considered in the determination of scientific merit and the priority score: 1. Collaborative Strengths. o Are plans for collaborations provided for individual research objectives? o To what extent are these collaborations necessary for the successful completion of the research plan? o Are there adequate plans for effective interaction and coordination with the Network components, the SC, the DMCC and the NCI? o Do the investigators state their willingness to collaborate and share information? o Do the investigators state their willingness to abide by the priorities and policies agreed upon by the SC for collaborative studies? o Have the applicants proposed sound strategies for communication among themselves, with the other Network components, and with the NCI? 2. Budget. For U01 applications, does the apportionment of the budget for biomarkers development, characterization, and/or technology innovation indicate that the applicants understand the requirements of managing a Biomarker Developmental Laboratory in the Network enterprise? For the NIH intramural project applications, is the commitment of effort appropriate to the scope of the project, and are the resources and environment adequate to support the project? PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed. (See criteria included in the section on Federal Citations, below.) Describe accrual and collection of specimens available for each disease site that will be used in the study in compliance with HIPPA. INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. (See Inclusion Criteria in the sections on Federal Citations, below.) CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to be used in the project, the five items described under Section f of the PHS 398 research grant application instructions (rev. 5/2001) will be assessed. ADDITIONAL REVIEW CONSIDERATIONS Sharing Research Data Applicants requesting $500,000 or more in direct costs in any year of the proposed research must include a data sharing plan in their application. The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or priority score. (See Federal Citations, below.) BUDGET: The reasonableness of the proposed budget and the requested period of support in relation to the proposed research. RECEIPT AND REVIEW SCHEDULE Letter of Intent Receipt Date: November 22, 2004 Application Receipt Date: December 20, 2004 Peer Review Date: March 2005 Council Review: June 2005 Earliest Anticipated Start Date: July 1, 2005 AWARD CRITERIA Award criteria that will be used to make award decisions include: o Scientific merit (as determined by peer review); o Availability of funds; and o Programmatic priorities. REQUIRED FEDERAL CITATIONS ANIMAL WELFARE PROTECTION: Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf), as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm), as applicable. HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained. See http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm DATA AND SAFETY MONITORING PLAN: Data and safety monitoring is required for all types of clinical trials, including physiologic, toxicity, and dose-finding studies (phase I); efficacy studies (phase II); efficacy, effectiveness and comparative trials (phase III). The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risk to the participants. Research components involving Phase I and II clinical trials must include provisions for assessment of patient eligibility and status, rigorous data management, quality assurance, and auditing procedures. In addition, it is NIH policy that all clinical trials require data and safety monitoring, with the method and degree of monitoring being commensurate with the risks (See NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, June 12, 1998, at http://grants.nih.gov/grants/guide/notice-files/not98-084.html.) Clinical trials supported or performed by NCI require special considerations. The method and degree of monitoring should be commensurate with the degree of risk involved in participation and the size and complexity of the clinical trial. Monitoring exists on a continuum from monitoring by the principal investigator/project manager or NCI program staff or a Data and Safety Monitoring Board (DSMB). These monitoring activities are distinct from the requirement for study review and approval by an Institutional review Board (IRB). For details about the Policy for the NCI for Data and Safety Monitoring of Clinical trials, see http://deainfo.nci.nih.gov/grantspolicies/datasafety.htm. For Phase I and II clinical trials, investigators must submit a general description of the data and safety monitoring plan as part of the research application. For additional information, see NIH Guide Notice on “Further Guidance on a Data and Safety Monitoring for Phase I and II Trials” at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html. Information concerning essential elements of data safety monitoring plans for clinical trials funded by the NCI is available at http://www.cancer.gov/clinical_trials/. SHARING RESEARCH DATA: Investigators submitting an NIH application seeking more than $500,000 or more in direct costs in any single year are expected to include a plan for data sharing (http://grants.nih.gov/grants/policy/data_sharing) or state why this is not possible. Investigators should seek guidance from their institutions, on issues related to institutional policies, local IRB rules, as well as local, state and Federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the priority score. INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research - Amended, October, 2001," published in the NIH Guide for Grants and Contracts on October 9, 2001 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines are available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: (a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and (b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences. INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS: The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects that is available at http://grants.nih.gov/grants/funding/children/children.htm. REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy requires education on the protection of human subject participants for all investigators submitting NIH proposals for research involving human subjects. You will find this policy announcement in the NIH Guide for Grants and Contracts Announcement, dated June 5, 2000, at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html. A continuing education program in the protection of human participants in research is available online at: http://cme.nci.nih.gov/. HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (see http://escr.nih.gov). It is the responsibility of the applicant to provide, in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research. Applications that do not provide this information will be returned without review. PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The Office of Management and Budget (OMB) Circular A-110 has been revised to provide public access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this RFA in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award. STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The Department of Health and Human Services (DHHS) issued final modification to the “Standards for Privacy of Individually Identifiable Health Information,” the “Privacy Rule,” on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR). Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on “Am I a covered entity?” Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html. URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site. HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This RFA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople. AUTHORITY AND REGULATIONS: This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)(cite appropriate authorizations) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92 (cite relevant regulations). All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm (Also cite other relevant policies.) The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. References Early Detection Research Network. Disease Markers. Volume 15, No. 4, December 1999, pages 213-219. Pepe, M.S., Etzioni, R., Feng, Z., Potter, J., Thompson, M. L., Thornquist, M., Yasui, Y. (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 93, 1054-1061.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892